The STOP-TBI trial aims to investigate the safety, efficacy and dosing parameters of a novel perfluorocarbon emulsion, Oxycyte PFC that is given intravenously to traumatic brain injury patients.
As per the terms of the agreement, Pharming is entitled to receive certain commercial, regulatory and clinical milestones from MegaPharm. MegaPharm will buy its commercial supply of Ruconest
Avonex Pen (Avonex 30mcg/0.5ml solution for injection, in pre-filled pen) is a single-use, once-a-week, intramuscular autoinjector which includes a protective injector shield that conceals the needle prior to
Oral ridaforolimus, an investigational mTOR inhibitor, was granted a special protocol assessment (SPA) by the US Food and Drug Administration (FDA) for the SUCCEED trial. Ridaforolimus improved progression-free
Letrozole Tablets, USP is an aromatase inhibitor indicated as an adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. Letrozole Tablets, which are therapeutically equivalent
InfoMedics is a provider of patient-physician communications programs for pharmaceutical clients in more than 20 countries outside the US. The company has also expanded its patient-physician communication programs
As per the agreement, Cellectis is responsible for supplying preselected meganucleases to VitamFero to utilize in the development of vaccines against parasites responsible for toxoplasmosis, neosporosis, and others.
Donepezil Hydrochloride tablets (5mg and 10mg strengths) are bioequivalent generic version of Aricept tablets, a prescription medicine indicated as a treatment for mild, moderate and severe Alzheimer’s disease.
The study evaluated Bayer‘s experimental compound, Alpharadin, licensed from Algeta, in patients who were suffering from castration-resistant prostate cancer (CRPC) and symptomatic bone metastases. As recommended by an
PharmaPros is a technology solutions provider specializing in data and workflow management for clinical trials. Dataflow Manager is expected to offer an operational interface for the management of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.